IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 301–400 of 1,011
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Koblish, H. K., Wu, L., Wang, L.-C. S., Liu, P. C. C., Wynn, R., Rios‐Doria, J., Spitz, S., Liu, H., Volgina, A., Zolotarjova, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1156 · Cited by 158
D’Angelo, S. P., Lebbé, C., Mortier, L., Brohl, A. S., Fazio, N., Grob, J., Prinzi, N., Hanna, G. J., Hassel, J. C., Kiecker, F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002646 · Cited by 155
Fang, D. D., Tang, Q., Kong, Y., Wang, Q., Gu, J., Fang, X., Zou, P., Rong, T., Wang, J., Yang, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0750-6 · Cited by 151
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Zamarin, D., Ricca, J. M., Sadekova, S., Oseledchyk, A., Yu, Y., Blumenschein, W. M., Wong, J., Gigoux, M., Merghoub, T., & Wolchok, J. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98047 · Cited by 147
Hsu, C., Ou, D., Bai, L., Chen, C., Lin, L., Huang, S.-F. K., Cheng, A., Jeng, Y., & Hsu, C. (2021) · Liver Cancer · doi:10.1159/000515305 · Cited by 160
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Arang, N., & Gutkind, J. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.14017 · Cited by 157
Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarfò, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0181 · Cited by 165
Mao, W., Cai, Y., Chen, D., Jiang, G., Xu, Y., Chen, R., Wang, F., Wang, X., Zheng, M., Zhao, X., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161940 · Cited by 145
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 166
Novel therapies for malignant pleural mesothelioma
Scherpereel, A., Wallyn, F., Albelda, S. Μ., & Munck, C. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30100-1 · Cited by 163
Immune evasion by cancer stem cells
Tsuchiya, H., & Shiota, G. (2021) · Regenerative Therapy · doi:10.1016/j.reth.2021.02.006 · Cited by 160
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
Kumar, A., Watkins, R., & Vilgelm, A. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690499 · Cited by 159
“These include various tumor expression signatures such as an interferon signature (137), increased leukocyte infiltration (138), and the presence of inhibitory immune subsets, such as myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM).”
BackgroundLuke, J. J., Patel, M. R., Blumenschein, G. R., Hamilton, E. P., Chmielowski, B., Ulahannan, S. V., Connolly, R. M., Santa-Maria, C. A., Wang, J., Bahadur, S. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02593-0 · Cited by 156
Advances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 168
Dummer, R., Gyorki, D. E., Hyngstrom, J. R., Berger, A. C., Conry, R. M., Демидов, Л. В., Sharma, A., Treichel, S., Radcliffe, H.-S., Gorski, K. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01510-7 · Cited by 157
Tai, D. W.-M., Loke, K. S. H., Gogna, A., Kaya, N. A., Tan, S. H., Hennedige, T. P., Ng, D. C., Irani, F. G., Lee, J. J. X., Lim, J. Q., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00305-8 · Cited by 158
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Pataskar, A., Champagne, J., Nagel, R., Kenski, J. C. N., Laos, M., Michaux, J., Pak, H. S., Bleijerveld, O. B., Mordente, K., Navarro, J. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04499-2 · Cited by 152
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han, J., Wu, M., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190333 · Cited by 169
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
Damotte, D., Warren, S., Arrondeau, J., Boudou-Rouquette, P., Mansuet-Lupo, A., Biton, J., Ouakrim, H., Alifano, M., Gervais, C., Bellesoeur, A., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2100-3 · Cited by 148
Radiation therapy-induced remodeling of the tumor immune microenvironment
Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 159
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 149
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 200
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Melero, I., Luken, M. D. M., de Velasco, G., Garralda, E., Martín-Liberal, J., Joerger, M., Alonso, G., Goebeler, M.-E., Schüler, M., König, D., et al. (2024) · Nature · doi:10.1038/s41586-024-08305-z · Cited by 165
Lu, C., Klement, J. D., Ibrahim, M. L., Xiao, W. L., Redd, P. S., Nayak-Kapoor, A., Zhou, G., & Liu, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0635-8 · Cited by 157
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C. S., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 137
Type I and II Interferons in the Anti-Tumor Immune Response
Fenton, S. E., Saleiro, D., & Platanias, L. C. (2021) · Cancers · doi:10.3390/cancers13051037 · Cited by 157
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Lapuente-Santana, Ó., van Genderen, M., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 136
Zhang, N., Zhang, H., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.74281 · Cited by 140
Bommareddy, P. K., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1591875 · Cited by 136
Ye, B., Fan, J., Xue, L., Yu, Z., Luo, P., Jiang, A., Xie, J., Li, Q., Liang, X., Tan, J., et al. (2025) · iMeta · doi:10.1002/imt2.70011 · Cited by 152
Thompson, J. C., Hwang, W.-T., Davis, C., Deshpande, C., Jeffries, S., Rajpurohit, Y., Krishna, V., Smirnov, D., Verona, R., Lorenzi, M. V., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.012 · Cited by 136
Bergamaschi, C., Pandit, H., Nagy, B. A., Stellas, D., Jensen, S. M., Bear, J., Cam, M., Valentin, A., Fox, B. A., Felber, B. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000599 · Cited by 141
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
Xiao, J., Li, W., Huang, Y. Y., Huang, M., Li, S., Zhai, X., Zhao, J., Gao, C., Xie, W., Qin, H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-07942-1 · Cited by 141
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Aznar, M. A., Planelles, L., Perez-Olivares, M., Molina, C., Garasa, S., Etxeberría, I., Perez, G., Rodriguez, I., Bolaños, E., Lopez-Casas, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0568-2 · Cited by 132
Toll-Like Receptor 9 Agonists in Cancer
Karapetyan, L., Luke, J. J., & Davar, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247050 · Cited by 147
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“On the other hand, under certain circumstances they exhibit immunosuppressive properties.(76,77) In particular, recent studies have identified the presence of B cells”
BackgroundBommareddy, P. K., Aspromonte, S., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau0417 · Cited by 132
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
Fan, Y., & He, S. (2022) · Cancer Management and Research · doi:10.2147/cmar.s316700 · Cited by 144
Kelly, R. J., Lee, J., Bang, Y., Almhanna, K., Blum-Murphy, M. A., Catenacci, D. V. T., Chung, H. C., Wainberg, Z. A., Gibson, M. K., Lee, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2443 · Cited by 144
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 147
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 153
Chen, S.-H., Dominik, P. K., Stanfield, J., Ding, S., Yang, W., Kurd, N. S., Llewellyn, R. A., Heyen, J. R. R., Wang, C., Melton, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003464 · Cited by 142
Xiong, W., Qi, L., Jiang, N., Zhao, Q., Chen, L., Jiang, X., Li, Y., Zhou, Z., & Shen, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21743 · Cited by 137
Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
Guo, Y., Liu, Y., Wu, W., Ling, D., Zhang, Q., Peng, Z. M., & Hu, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121018 · Cited by 143
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
Zeng, Z., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Gu, S. S., Zhang, Y., Liu, Y., Wang, X., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab804 · Cited by 143
Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc4220 · Cited by 133
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
Verschoor, Y. L., van de Haar, J., van den Berg, J. G., van Sandick, J. W., Kodach, L. L., van Dieren, J. M., Balduzzi, S., Grootscholten, C., Ijsselsteijn, M. E., Veenhof, A. A. F. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02758-x · Cited by 158
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 147
Tang, Z., Bai, Y., Fang, Q., Yuan, Y., Zeng, Q., Chen, S., Xu, T., Chen, J., Tan, L., Wang, C., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.011 · Cited by 153
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
Incorvaia, L., Fanale, D., Badalamenti, G., Barraco, N., Bono, M., Corsini, L. R., Galvano, A., Gristina, V., Listì, A., Vieni, S., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01057-7 · Cited by 143
Engineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 138
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Augustin, R. C., Leone, R. D., Naing, A., Fong, L. H., Bao, R., & Luke, J. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004089 · Cited by 138
High endothelial venules in cancer: Regulation, function, and therapeutic implication
Vella, G., Hua, Y., & Bergers, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.002 · Cited by 138
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 142
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 136
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells
Fang, C., Weng, T., Hu, S., Yuan, Z., Xiong, H., Huang, B. Y., Cai, Y., Li, L., & Fu, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1962591 · Cited by 142
Zeng, Q., Klein, C., Caruso, S., Maille, P., Laleh, N. G., Sommacale, D., Laurent, A., Amaddeo, G., Gentien, D., Rapinat, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.018 · Cited by 118
Asleh, K., Negri, G. L., Miko, S. E. S., Colborne, S., Hughes, C. S., Wang, X. Q., Gao, D., Gilks, C. B., Chia, S., Nielsen, T. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28524-0 · Cited by 135
Eicosanoids in Cancer: New Roles in Immunoregulation
Johnson, A. M., Kleczko, E. K., & Nemenoff, R. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595498 · Cited by 124
“have developed a gene signature involving responsiveness to interferon gamma (IFNγ) associate with response (Ayers et al., 2017).”
BackgroundReardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 136
Seremet, T., Jansen, Y., Planken, S., Njimi, H., Delaunoy, M., El Housni, H., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 119
Aggen, D. H., Ager, C. R., Obradović, A., Chowdhury, N., Ghasemzadeh, A., Mao, W., Chaimowitz, M. G., Bujanda, Z. A. L., Spina, C. S., Hawley, J. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1610 · Cited by 132
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Liu, D., Heij, L. R., Czigány, Z., Dahl, E., Lang, S. A., Ulmer, T. F., Luedde, T., Neumann, U. P., & Bednarsch, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02340-2 · Cited by 134
Bergerot, P., Lamb, P., Wang, E., & Pal, S. K. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1399 · Cited by 124
Song, S. G., Kim, S., Koh, J., Yim, J., Han, B., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02840-0 · Cited by 133
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0158 · Cited by 124
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia
Gil Vazquez, E., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., Schenck, R. O., Wouters, V. M., Wirapati, P., Gilroy, K., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.008 · Cited by 125
Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 131
Jílková, Z. M., Aspord, C., & Decaens, T. (2019) · Cancers · doi:10.3390/cancers11101554 · Cited by 124
TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource
Chen, Z., Luo, Z., Zhang, D., Li, H., Liu, X., Zhu, K., Zhang, H., Wang, Z., Zhou, P., Ren, J. M., et al. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.08.004 · Cited by 128
Belmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 126
Lim, R. J., Salehi‐Rad, R., Tran, L. M., Oh, M. S., Dumitras, C., Crosson, W. P., Li, R., Patel, T. S., Man, S., Yean, C. E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101479 · Cited by 173
Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002181 · Cited by 119
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Ganesh, S., Shui, X., Craig, K. P., Park, J., Wang, W., Brown, B. D., & Abrams, M. T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.005 · Cited by 116
de la Iglesia, J. V., Slebos, R. J. C., Martin‐Gomez, L., Wang, X., Teer, J. K., Tan, A. C., Gerke, T. A., Aden-Buie, G., van Veen, T., Masannat, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1769 · Cited by 126
Zhang, K., Hong, X., Song, Z., Xu, Y., Li, C., Wang, G., Zhang, Y., Zhao, X., Zhao, Z., Zhao, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3976 · Cited by 128
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 118
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 134
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 129
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
Cottrell, T. R., & Taube, J. M. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000301 · Cited by 129
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Osorio, J. C., Arbour, K. C., Le, D. T., Durham, J. N., Plodkowski, A. J., Halpenny, D. F., Ginsberg, M. S., Sawan, P., Crompton, J. G., Yu, H. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00709 · Cited by 119
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 134
Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3206 · Cited by 113
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Liu, X., Choi, M. G., Kim, K., Kim, K., Kim, S. T., Park, S. H., Cristescu, R., Peter, S. A., & Lee, J. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152881 · Cited by 127
Thompson, J. C., Davis, C. W., Deshpande, C. G., Hwang, W., Jeffries, S., Huang, A. C. C., Mitchell, T. C., Langer, C. J., & Albelda, S. Μ. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000974 · Cited by 129
Hutchinson, K. E., Yost, S. E., Chang, C.-W., Johnson, R. M., Carr, A. R., McAdam, P. R., Halligan, D. L., Chang, C.-C., Schmolze, D., Liang, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1773 · Cited by 114
DNA hypermethylation during tuberculosis dampens host immune responsiveness
DiNardo, A. R., Rajapakshe, K., Nishiguchi, T., Mtetwa, G., Dlamini, Q., Kahari, J., Mahapatra, S., Kay, A., Gugu, M., Mace, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134622 · Cited by 130
“Since patients with TB exhibited DNA hypermethylation of the IL-12/IFN-γ signaling pathway in CD4+ Th cells, NK cells, and CTLs, we postulated that they would also exhibit decreased IFN-γ–inducible gene upregulation using a previously described 10-gene IFN-γ–inducible score (15, 29, 30).”
MethodResultKlümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 124
Powles, T. B., Sridhar, S. S., Loriot, Y., Bellmunt, J., Mu, X. J., Ching, K. A., Pu, J., Sternberg, C. N., Petrylak, D. P., Tambaro, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01579-0 · Cited by 122
Zha, H., Wang, X., Zhu, Y., Chen, D., Han, X., Yang, F., Gao, J., Hu, C., Shu, C., Feng, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0272 · Cited by 106
Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 116
“73 74 Cancer immunotherapy is mechanistically different from other treatment modalities, such as cytotoxic therapies and small module inhibitors, as it can target the TME as well as the tumor itself.”
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.